No of your stocks has realtime/relevant news articles that can be accessed.
Take a look into our News feed to read about recent price changes and analysis.
Sentiment statistics ?
Please use our Financial history templates to chart, read and compare all 10'Q filings in depth.
|Market Cap||21.7 billion|
|Outstanding Shares||239.8 million|
|Sector Name||Health Care|
|Country Short Name||DE|
|Announcement Earnings||2023-11-06 13:00:00+00:00|
There is no dividend data to display. Refer our Dividend calendar for other accurate data.
Please sign up and become a member to view all risk profiles.
Use our 'Focus' approach as text-and chart based summaries of the financial standing for a company. They are solely focussing on the company's market, risks and chances.
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers;